|
|
| NEW Labeled Antibodies: Anti-CD-3ε, Anti-CD79α |
|
|
Leveraging its expertise
in both detection reagents and antibodies, AnaSpec is pleased to introduce
a new series of labeled anti-CD-3ε
and anti-CD79a
antibodies. With a range of classic labels like biotin, FAM, and FITC
as well as AnaSpec’s proprietary HiLyte Fluor™ labels, AnaSpec’s line of anti-CD-3ε
, anti-CD79α antibodies provide a research-ready spectrum of detection
possibilities for use in applications such as flow cytometry, immunohistochemistry and fluorescent in-situ hybridization.
Custom labeling service
for all our primary antibodies is available. Available labels include HiLyte Fluor™ dyes, HRP, AP, biotin, R-PE (R-phycoerythrin)
and B-PE (B-phycoerythrin). Please inquire at service@anaspec.com
Click here to request
AnaSpec’s Detection Reagents & Kits catalog.
Anti-CD-3ε
T cell activation through the T cell antigen receptor (TCR) involves the cytoplasmic
tails of the CD3 subunits CD3g, CD3d, CD3e and
CD3z.1,2 These CD3 subunits are structurally related members of the immunoglobulins
super family encoded by closely linked genes on human chromosome 11.1
The CD3 components have long cytoplasmic tails that associate with cytoplasmic
signal transduction molecules. This association is mediated at least in part
by a double tyrosine-based motif present in a single copy in the CD3 subunits.
CD3e may play a role in TCR-induced growth arrest, cell survival and proliferation.3
Rabbit anti-CD3e polyclonal antibody was raised against a synthetic peptide from the human CD3
protein, epsilon chain, only one amino acid different from mouse and rat origins.
| Cat# |
Form |
Unit Size |
| 29588 |
Unconjugated |
50
mg |
| 29588-BIOT |
Biotinylated |
50
mg |
| 29588-FAM |
FAM-labeled |
50
mg |
| 29588-TAMR |
TAMRA-labeled |
50
mg |
| 29588-AMCA |
AMCA-labeled |
50
mg |
| 29588-FITC |
FITC-labeled |
50
mg |
| 29588-H488 |
HiLyte Fluor™ 488-labeled |
50
mg |
| 29588-H555 |
HiLyte Fluor™ 555-labeled |
50
mg |
| 29588-H647 |
HiLyte Fluor™ 647-labeled |
50
mg |
| 29588-H750 |
HiLyte Fluor™ 750-labeled |
50
mg |
|
|
IHC of Human tonsil probed with anti-CD3ε (Cat# 29588).
Anti-CD-79α
The CD79 molecule, comprising two polypeptide chains, mb-1 (CD79α) and B29 (CD79β),
is physically associated in the B-cell membrane with immunoglobulins to constitute
the B cell antigen receptor (BCR).4,5 The CD79α/β heterodimer interacts
with at least one tyrosine kinase (Lyn).6 Induction of tyrosine kinase
activity after antigen binding causes phosphorylation of the CD79α/β dimer,
and also of other molecules, thereby initiating intracellular signaling.6
Almost all acute lymphoblastic leukemias of precursor B cell type are positive
when tested with CD79α antibodies.7-9 Rabbit anti-CD79α polyclonal
antibody was raised against a synthetic peptide corresponding to human and mouse
CD79α.
|
|
IHC of Human tonsil probed with anti-CD79α(Cat# 29560).
| Cat# |
Form |
Unit Size |
| 29560 |
Unconjugated |
50
mg |
| 29560-BIOT |
Biotinylated |
50
mg |
| 29560-FAM |
FAM-labeled |
50
mg |
| 29560-TAMR |
TAMRA-labeled |
50
mg |
| 29560-AMCA |
AMCA-labeled |
50
mg |
| 29560-FITC |
FITC-labeled |
50
mg |
| 29560-H488 |
HiLyte Fluor™ 488-labeled |
50
mg |
| 29560-H555 |
HiLyte Fluor™ 555-labeled |
50
mg |
| 29560-H647 |
HiLyte Fluor™ 647-labeled |
50
mg |
| 29560-H750 |
HiLyte Fluor™ 750-labeled |
50
mg |
Custom Labeling Service Available for the following:
| Label |
Abs/Em |
| AP |
N/A |
| HRP |
N/A |
| Biotin |
N/A |
| AMCA |
353/442 |
| FAM |
492/518 |
| FITC |
493/517 |
| TAMRA |
542/568 |
| HiLyteTM 488 |
498/525 |
| HiLyteTM 555 |
552/569 |
| HiLyteTM 647 |
649/674 |
| HiLyteTM 750 |
753/778 |
| R-PE |
565/575 |
| B-PE |
545/575 |
Related Products:
AnaTag
Labeling Kits
To view a recent poster on HiLyte FluorTM 750, please click here.
References:
1.
Clevers, H. et al. Annu. Rev.
Immunol. 6, 629(1988).
2.
Malissen, B. et al. Curr. Opin.
Immunol. 5, 324 (1993).
3.
Gil, D. et al. J. Biol. Chem.
276, 11174 (2001).
4.
Mason, DY. et al. Blood 86, 1453 (1995).
5.
Payelle-Brogard, B. et al. Blood 94, 3516 (1999).
6.
Chu, PG. et al. Appl. Immunohistochem. Mol. Morphol. 9, 97 (2001).
7.
Verschuren, MCM. et al. Leukemia 7, 1931 (1993).
8.
Buccheri, V. et al. Blood 82, 853 (1993).
9.
Payelle-Brogard, et al. Br. J. Hematology 118, 976 (2002).
|
|
|
|
|
|
|
|
|
